A Study on Intima Media Thickness (IMT) in Middle-aged Subjects
NCT ID: NCT00784264
Last Updated: 2010-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2008-10-31
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CIMT and Plaque Assessment Findings in Subjects Undergoing Stress Echocardiography For Risk Stratification
NCT02245048
Carotid Ultrasound Sub-Study of the Familial Atherosclerosis Study-observational Study
NCT00976014
Epidemiology of Carotid IMT Progression in MESA - Ancillary Study
NCT00063440
Evaluate the Precision of ABL-101 Perfluorocarbon and Fluorine-19 MRI for the Mapping of Atherosclerotic Plaque Composition and Inflammation in Patients Undergoing Carotid Endarterectomy
NCT06850324
Intravascular Imaging Evaluated Calcified Nodule China Registry
NCT07262359
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Waist circumference: male more than 90 cm; female more than 80 cm.
Exclusion Criteria
* Presence of known cardiovascular diseases including cerebro-vascular disease, coronary heart disease and peripheral artery disease.
* Presence of any active major diseases that may interfere the physical conditions and body weight of subjects during the study period, which include malignancy, infection, renal or liver function impairment, recent major surgery (within 3 months).
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Karen Yuen
Role: STUDY_DIRECTOR
AstraZeneca Hong Kong Ltd
Chun chung Chow, MD
Role: PRINCIPAL_INVESTIGATOR
Prince of Wales Hospital, Shatin, Hong Kong
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Hong Kong, , Hong Kong
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-CHK-DUM-2008/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.